
BETTER LONG-TERM DATA. PERIOD.

THE ONLY FDA APPROVED^{1,2} LONG-TERM RESULTS

miner la ES



LONG-TERM DATA 7X REDUCTION IN HYSTERECTOMY RATE^{1,2,3}

THE ONLY FDA APPROVED¹² LONG-TERM RESULTS INCIDENCE OF HYSTERECTOMY

Μ	N	ER	VA	ES
τv	oard	E Fol		un

5 rears Follow-up



Minerva Single Arm Study ¹	One Year		Three Years	
n=110	# Patients	%	# Patients	%
Hysterectomy N (%)	0	0.0%	1	0.9%

3	Years	Follow-up	

NovaSure



NovaSure RCT Study ²	One Year		Three Years	
n=175	# Patients	%	# Patients	%
Hysterectomy N (%)	3	1.7%	11	6.3%

1. FDA Approved Labeling: Minerva Endometrial Ablation System [Operator's Manual]. Redwood City, CA: Minerva Surgical, Inc; L0001
2. FDA Approved Labeling: NovaSure Impedance Controlled Endometrial Ablation System [Instructions For Use and Controller Operator's Manual]. Marlborough, MA: Hologic, Inc; 2014.
3. Not based on a head-to-head study
© 2019 All rights reserved. Minerva and Minerva ES are registered trademarks of Minerva Surgical, Inc.